Nav: Home

CD4+ T-cell count useful to assess antiretroviral therapy response in HTLV-1/HIV patients?

March 17, 2017

The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. Any differences in the CD4+ T-cell counts were expected to disappear once the co-infected and mono-infected patients began to fail their antiretroviral therapy (ART) regimens.

Instead, the authors found that HTLV-1/HIVco-infected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/μL higher than their HIV mono-infected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients.

HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient's response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences.

Against this background, recent scientific research has begun to show that HIV viral load testing can be both an accurate and cost-effective treatment monitoring strategy. The present study was based in the KwaZulu-Natal province of South Africa and used patient data from a poor and rural community at the epicentre of the global HIV epidemic.
-end-
For more information about the research, please visit: http://www.eurekaselect.com/150147

Reference: Vandormael, A.; (2017). CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients. Current HIV Research., DOI: 10.2174/1570162X15666170216114917

Bentham Science Publishers

Related Hiv Articles:

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.
Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.
The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
First ever living donor HIV-to-HIV kidney transplant
For the first time, a person living with HIV has donated a kidney to a transplant recipient also living with HIV.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
HIV RNA expression inhibitors may restore immune function in HIV-infected individuals
Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity.
More HIV News and HIV Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 2: Every Day is Ignaz Semmelweis Day
It began with a tweet: "EVERY DAY IS IGNAZ SEMMELWEIS DAY." Carl Zimmer – tweet author, acclaimed science writer and friend of the show – tells the story of a mysterious, deadly illness that struck 19th century Vienna, and the ill-fated hero who uncovered its cure ... and gave us our best weapon (so far) against the current global pandemic. This episode was reported and produced with help from Bethel Habte and Latif Nasser. Support Radiolab today at Radiolab.org/donate.